hasBioavailability

P37223

predicate

Indicates that a substance has a specified degree or measure of bioavailability, i.e., the proportion that enters circulation and can have an active effect.

Try in SPARQL

All labels observed (2)

Label	Occurrences
hasBioavailability canonical	42
bioavailability	3

Description generation (PDg)

The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.

Instruction

Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning.  
# Instructions
Focus on describing the relationship, not the entities themselves. 
# Response Format
Begin the description with \' Indicates...\'

Input

Predicate: hasBioavailability

Generated description

Indicates that a substance has a specified degree or measure of bioavailability, i.e., the proportion that enters circulation and can have an active effect.

Sample triples (45)

Subject	Object
Xarelto	high oral bioavailability at lower doses ⓘ
Imbruvica	variable and food-dependent ⓘ
oseltamivir	high oral bioavailability ⓘ
zanamivir	very low oral bioavailability ⓘ
rivastigmine	approximately 40 percent at therapeutic doses ⓘ
memantine surface form: Memantine	approximately 100% ⓘ
riluzole surface form: Riluzole	about 60 percent ⓘ
methotrexate	approximately 60–70% (oral, low doses) ⓘ
apixaban	approximately 50 percent ⓘ
bortezomib	100% (intravenous) ⓘ
dabigatran	approximately 6 percent ⓘ
rimonabant	approximately 20% to 30% ⓘ
cyclophosphamide	75–90% ⓘ
docetaxel surface form: Docetaxel	100% (intravenous) via predicate surface "bioavailability" ⓘ
albendazole surface form: Albendazole	low oral bioavailability ⓘ
pyrantel pamoate surface form: Pyrantel pamoate	poorly absorbed from gastrointestinal tract ⓘ
H2 receptor antagonist cimetidine surface form: cimetidine	about 60–70 percent ⓘ
Tagrisso	high oral bioavailability ⓘ
amphotericin B surface form: Amphotericin B	very low oral bioavailability ⓘ
posaconazole	food-dependent ⓘ
fluconazole	high oral bioavailability ⓘ
thioridazine	high oral bioavailability ⓘ
Chromium Picolinate surface form: Chromium picolinate	higher than some other chromium salts ⓘ
dihydroartemisinin	high oral bioavailability ⓘ
benserazide surface form: Benserazide	low ⓘ
carbidopa	about 40–70% via predicate surface "bioavailability" ⓘ
phenytoin	variable ⓘ
probenecid	high oral bioavailability ⓘ
ketoconazole	variable oral bioavailability ⓘ
itraconazole	variable and formulation-dependent ⓘ
clarithromycin	about 50% ⓘ
carbamazepine	70–85% ⓘ
terfenadine surface form: Terfenadine	low due to first-pass metabolism ⓘ
danazol surface form: Danazol	variable oral bioavailability ⓘ
cyclosporine A surface form: Cyclosporine A	20–50% ⓘ
quinidine	high oral bioavailability ⓘ
sulfasalazine	poor ⓘ
pomalidomide	high oral bioavailability ⓘ
topiramate	about 80–90% ⓘ
fenfluramine	high oral bioavailability ⓘ
lamotrigine	approximately 98 percent ⓘ
acalabrutinib	oral, moderate via predicate surface "bioavailability" ⓘ
lapatinib	low to moderate oral bioavailability ⓘ
rufinamide	increased with food ⓘ
pyrazinamide surface form: Pyrazinamide	high oral bioavailability ⓘ